Novo Nordisk Wins Dutch Injunction in Ceban Semaglutide Patent Case

MT Newswires Live08-05 22:33

Novo Nordisk (NVO) said Wednesday it won a preliminary injunction in the Netherlands against Ceban Ziekenhuisfarmacie B.V. in a patent-infringement case involving its compounded semaglutide nasal spray.

The District Court of The Hague ordered Ceban to stop selling the nasal spray immediately, noting that Ceban infringed Novo Nordisk's supplementary protection certificate covering semaglutide, Novo said.

Novo Nordisk said that under the ruling, Ceban has to remove references to the product from relevant listings and websites, provide information about its commercial supply chain, and reimburse its legal costs.

Ceban did not immediately respond to MT Newswires' request for comment.

Shares of Novo Nordisk were up 2.6% in Wednesday trading.

Price: 45.53, Change: +1.25, Percent Change: +2.81

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2657523270?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 22:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2657523270","market":"sg","top_or_hot":-1,"title":"Novo Nordisk Wins Dutch Injunction in Ceban Semaglutide Patent Case","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> (NVO) said Wednesday it won a preliminary injunction in the Netherlands against Ceban Ziekenhuisfarmacie B.V. in a patent-infringement case involving its compounded semaglutide nasal spray.</p><p>The District Court of The Hague ordered Ceban to stop selling the nasal spray immediately, noting that Ceban infringed Novo Nordisk's supplementary protection certificate covering semaglutide, Novo said.</p><p>Novo Nordisk said that under the ruling, Ceban has to remove references to the product from relevant listings and websites, provide information about its commercial supply chain, and reimburse its legal costs.</p><p>Ceban did not immediately respond to MT Newswires' request for comment.</p><p>Shares of Novo Nordisk were up 2.6% in Wednesday trading.</p><p>Price: 45.53, Change: +1.25, Percent Change: +2.81</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Wins Dutch Injunction in Ceban Semaglutide Patent Case</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Wins Dutch Injunction in Ceban Semaglutide Patent Case\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-05 22:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> (NVO) said Wednesday it won a preliminary injunction in the Netherlands against Ceban Ziekenhuisfarmacie B.V. in a patent-infringement case involving its compounded semaglutide nasal spray.</p><p>The District Court of The Hague ordered Ceban to stop selling the nasal spray immediately, noting that Ceban infringed Novo Nordisk's supplementary protection certificate covering semaglutide, Novo said.</p><p>Novo Nordisk said that under the ruling, Ceban has to remove references to the product from relevant listings and websites, provide information about its commercial supply chain, and reimburse its legal costs.</p><p>Ceban did not immediately respond to MT Newswires' request for comment.</p><p>Shares of Novo Nordisk were up 2.6% in Wednesday trading.</p><p>Price: 45.53, Change: +1.25, Percent Change: +2.81</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2657523270","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2657523270","pubTimestamp":1785940439,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Novo Nordisk  said Wednesday it won a preliminary injunction in the Netherlands against Ceban Ziekenhuisfarmacie B.V. in a patent-infringement case involving its compounded semaglutide nasal spray.The District Court of The Hague ordered Ceban to stop selling the nasal spray immediately, noting that Ceban infringed Novo Nordisk's supplementary protection certificate covering semaglutide, Novo said.Novo Nordisk said that under the ruling, Ceban has to remove references to the product from relevant listings and websites, provide information about its commercial supply chain, and reimburse its legal costs.Ceban did not immediately respond to MT Newswires' request for comment.Shares of Novo Nordisk were up 2.6% in Wednesday trading.Price: 45.53, Change: +1.25, Percent Change: +2.81","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","OZEM":"Roundhill GLP-1 & Weight Loss ETF","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","THNR":"AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF","BK4532":"文艺复兴科技持仓","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4588":"碎股","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","NVOH":"Novo Nordisk A/S B Shares ADRhedged","BK4599":"减肥药","PPH":"VanEck Pharmaceutical ETF","NVOX":"2倍做多NVO ETF-Defiance","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","NVO":"诺和诺德"},"translate_title":"诺和诺德在Ceban Semaglutide专利案中赢得荷兰禁令","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.97,"PPH":0.6,"OZEM":0.6,"THNR":0.6,"NVOX":0.6,"NVOH":0.6},"content_text":"Novo Nordisk (NVO) said Wednesday it won a preliminary injunction in the Netherlands against Ceban Ziekenhuisfarmacie B.V. in a patent-infringement case involving its compounded semaglutide nasal spray.The District Court of The Hague ordered Ceban to stop selling the nasal spray immediately, noting that Ceban infringed Novo Nordisk's supplementary protection certificate covering semaglutide, Novo said.Novo Nordisk said that under the ruling, Ceban has to remove references to the product from relevant listings and websites, provide information about its commercial supply chain, and reimburse its legal costs.Ceban did not immediately respond to MT Newswires' request for comment.Shares of Novo Nordisk were up 2.6% in Wednesday trading.Price: 45.53, Change: +1.25, Percent Change: +2.81","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2657523270","isCrawlerRequest":true}